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Abstract
Background: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common
cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to
40% is due to more effective treatments of extracerebral sites with improved prognosis and increasing use of MRI
in diagnostics. A frequently administered, potent chemotherapeutic group of drugs for BC treatment are taxanes
usually used in the adjuvant and metastatic setting, which, however, have been suspected to be associated with a
higher incidence of BM. The aim of our study was to experimentally analyze the impact of the taxane docetaxel
(DTX) on brain metastasis formation, and to elucidate the underlying molecular mechanism.
Methods: A monocentric patient cohort was analyzed to determine the association of taxane treatment and BM
formation. To identify the specific impact of DTX, a murine brain metastatic model upon intracardial injection of
breast cancer cells was conducted. To approach the functional mechanism, dynamic contrast-enhanced MRI and
electron microscopy of mice as well as in-vitro transendothelial electrical resistance (TEER) and tracer permeability
assays using brain endothelial cells (EC) were carried out. PCR-based, immunohistochemical and immunoblotting
analyses with additional RNA sequencing of murine and human ECs were performed to explore the molecular
mechanisms by DTX treatment.
Results: Taxane treatment was associated with an increased rate of BM formation in the patient cohort and the
murine metastatic model. Functional studies did not show unequivocal alterations of blood-brain barrier properties
upon DTX treatment in-vivo, but in-vitro assays revealed a temporary DTX-related barrier disruption. We found
disturbance of tubulin structure and upregulation of tight junction marker claudin-5 in ECs. Furthermore,
upregulation of several members of the tubulin family and downregulation of tetraspanin-2 in both, murine and
human ECs, was induced.
Conclusion: In summary, a higher incidence of BM was associated with prior taxane treatment in both a patient
cohort and a murine mouse model. We could identify tubulin family members and tetraspanin-2 as potential
contributors for the destabilization of the blood-brain barrier. Further analyses are needed to decipher the exact
role of those alterations on tumor metastatic processes in the brain.
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Background
Breast cancer (BC) is the most common cancer in fe-
males, and also the most frequent cause of cancer-
related death in women in less developed countries, as
well as the second cause in more developed regions after
lung cancer [1]. In western countries it is not the pri-
mary tumour, but rather the metastatic disease, which is
the main cause of death [2]. Approximately 20% [99/
474] of women initially diagnosed with node-negative
BC and 40% [67/170] with node-positive BC, develop re-
current or metastatic disease, when treated with radical
mastectomy without chemotherapy [3]. In order to es-
tablish a distant metastasis, the tumor cells (TC) need to
pass a series of sequential steps, known as the metastatic
cascade: (i) invasion of adjacent tissue to intravasate in
the circulatory system, (ii) arrest within the capillary
bed, (iii) extravasation and finally (iv) proliferation at a
secondary site [4–7]. Brain metastases (BM) are the
most common intracranial tumors in adults being al-
most up to ten-fold more common than primary brain
tumors and some primary tumors, among others BC, ex-
hibit a particularly high BM incidence [8, 9]. For BM
formation in the CNS microenvironment, TCs need to
cross the blood-brain barrier (BBB) [10–12]. The BBB
consists of ECs, lined by pericytes, basement membrane
and astrocytes, forming a tight barrier around blood ves-
sels [11, 12]. After passing the BBB, TCs can grow in the
CNS, where they might potentially be protected from
therapeutic agents [13]. Diagnosis of BM leads to a dis-
mal prognosis with median overall survival of 13.8
months, ranging from 3.35 months to 25.3 months ac-
cording to the specific Graded Prognostic Assessment
Score [14]. Therefore, identification of possible risk fac-
tors, that lead to an increased amount of BM, are of high
importance. The current treatment approaches for BM
of BC patients are complex and numerous clinical trials
are ongoing. Chemotherapeutic strategies often include
members of the taxane family, leading to longer progres-
sion free- and overall survival [15, 16]. The traditional
main agents of the taxane family, that are used in BC,
are paclitaxel and DTX [17]. They act via permanent
stabilization of assembled microtubules, thus impairing
their dynamics and, consequently, cell mitosis and pro-
liferation. Furthermore, taxanes induce apoptosis, how-
ever the underlying mechanisms are not yet fully
understood [18, 19]. Controversial data exist regarding
the frequency of CNS-relapse in patients treated with
adjuvant taxanes, with some studies claiming the possi-
bility of increased risk of BM formation upon taxane
treatment [20–22]. Although taxanes are part of the
standard treatment regime in BC, there is a lack of data
concerning the impact of DTX treatment on BBB func-
tion and circulating TCs in the process of BM formation.
The aim of this study was to assess the impact of DTX
on BBB properties and formation of BM, using in-vitro
and an in-vivo models. Furthermore, we aimed at char-
acterizing the underlying mechanism.
Methods
Patient cohort and clinical data
Eighty breast cancer patients, treated in the Goethe-
University hospital Frankfurt am Main, department of
gynecology, from 2009 to 2015 were analyzed retrospect-
ively as a case-control study. Patients reaching the pri-
mary end-point “brain-metastases” (BM, cases: n = 40)
and patients without BM, but suffering from bone me-
tastases (BoM, controls: n = 40), were reviewed for ex-
posure to taxane-treatment prior to brain metastatic
disease. Patient characteristics are summarized in
Table 1. Statistical analysis was conducted using JMP 14
(SAS, Cary, U.S.A.), detailed description of the used stat-
istical methodology is provided in the corresponding fig-
ure legend.
Cell culture
The following cell types were used in our study: primary
mouse brain microvascular endothelial cells (MBMEC),
primary human brain microvascular endothelial cells
(HBMEC), murine immortalized brain endothelial cells
(bEnd5, obtained as described previously [23]) and hu-
man brain seeking breast-cancer cells MDA-MB-231-
BR-GFP (BR231, kind gift from Dr. P. Steeg, National
Cancer Institute, Bethesda MD 20892). ECs were cul-
tured on 0.1% gelatin-coated flasks/dishes in MCDB-131
complete medium as previously described [24], BR231
cells were cultured in complete medium (DMEM+Gluta-
MAX, 10%FCS, 100 U/mL penicillin, 100 μg/mL strepto-
mycin) in a humidified incubator. bEnd5 cells were
cultured as described previously [24] and used in order
to reduce the amount of animals required for generation
of primary MBMECs. All experiments were performed
on a confluent ECs monolayer. Cells were seeded at
150.000 cells/cm2 (bEnd5) or 100.000 cells/cm2
(MBMEC, HBMEC) and cultured for 3–7 days with re-
placement of medium once during that period to reduce
handling stress. If seeded on inserts (ThinCert™, 1 μm
pore diameter, 6–24 well plates, Greiner Bio-One, Lör-
rach, Germany), precoating with fibronectin (5 μg/cm2,
30 min, Sigma-Aldrich, St. Louis, MO, USA) was per-
formed. If seeded on culture plates (Greiner Bio-One, 6-
well), the wells were precoated with gelatine (0.1%, 30
min). For Western blotting and qPCR experiments treat-
ment was started after establishment of a confluent ECs
monolayer.
Isolation of primary brain microvascular ECs
For isolation of MBMECs a previously described, modi-
fied protocol was used [25]. Briefly, after isoflurane
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anesthesia C57BL/6-WT-mice (female, 7-12w) were cer-
vically dislocated and brains were harvested. After dis-
section of the cerebellum and olfactory bulb, removal of
meninges was performed by rolling the brains on an
autoclaved Whatman filter membrane (Schleicher &
Schuell, Dassel, Germany). For each biological replicate,
5–7 brains were pooled and homogenized in buffer A
[25] using a Dounce homogenizer (0.025 mm clearance,
Wheaton, Millville, NJ, USA) and centrifuged at 400x g
for 10 min at 4 °C.The supernatant was discarded and
the pellet was digested with 0.75% collagenase II
(Worthington, Lakewood, NJ, USA) in buffer A [(1,1:1
volume ratio; 1 h; shaking; 37 °C). After centrifugation
(400x g, 5 min, RT) and aspiration of the supernatant,
the pellet was resuspended in 25% BSA, centrifuged at
2000x g (30 min, 4 °C) in order to remove the myelin
layer. After enzymatic digestion of the pellet with colla-
genase/dispase (1 mg/mL, Roche, Basel, Switzerland) and
DNase I (1 μg/mL, Worthington) in buffer A (15 min,
37 °C) followed by centrifugation (400x g, 5 min, RT),
MBMECs were resuspended in MCDB-131 complete
medium [23] and seeded on 6-well plates pre-coated
with collagen type 1 (100 μg/cm2, Corning, Tewksbury,
MA, USA). Pure EC cultures were assured by puromycin
treatment (5 μg/mL, MCDB-131 complete medium; 48
h) as ECs resist puromycin through their endogenous
permeability-glycoprotein activity whereas other cell
Table 1 Patient characteristics including treatment and
pathological parameters
BoM/ nBM (N) BM (N)
patients 40 40
deceased 14 14
Taxane (#) 30 38
DTX 9 15
Paclitaxel 17 14
both 4 9
mean follow-up (##)
days 2492.95 2545.15
years 6.83 6.97
age primary diagnosis (##) years 55.6 52.4
neoadjuvant therapy (#)
yes 7 4
no 29 29
u 4 7
T (#)
T1 9 7
T2 15 13
T3 5 7
T4 6 7
Tx 1 1
Tis 0 1
u 4 4
N (#)
N0 10 16
N1 13 11
N2 5 4
N3 8 5
u 4 4
M (#)
M0 17 23
M1 15 8
Mx 1 1
u 7 8
grading (#) *
G1 4 0
G2 14 16
G3 9 17
u 13 7
ER (#) ***
+ 33 17
- 5 19
u 2 4
PR (#) *
Table 1 Patient characteristics including treatment and
pathological parameters (Continued)
BoM/ nBM (N) BM (N)
+ 26 15
- 12 20
u 2 5
HER2/neu (#) *
+ 13 12
- 24 21
u 3 7
triple negative (#) *
yes 3 9
no 34 27
u 3 4
intrinsic subtype (#) ***
luminal 34 19
basal-like 3 9
Erb-B2 overexpression 0 8
u 3 4
BoM bone metastasis, nBM no brain metastasis, BM brain metastasis, u
unknown. Statistical analysis was conducted using contingency analysis with
likelihood-ratio/ Pearson test (#) or analysis of variance using one-way ANOVA
(##). Significant differences are depicted as followed: * p<0.05; ** p<0.01;
*** p<0.001
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types are killed by the substrate. The puromycin-treated
medium was replaced by standard medium and cells
were used for the experiments afterwards. For isolation
of HBMECs, unaffected cortex tissue from patients suf-
fering from epilepsy (Additional file 3: Table S1) were
obtained from the Department of Neurosurgery (univer-
sity hospital, Frankfurt am Main) directly after oper-
ation. After cutting, samples were checked by an
experienced neuropathologist (MM, PNH) and proc-
essed directly following the same protocol as described
above, starting with homogenizing the samples in buffer
A using a Dounce homogenizer. Afterwards, cells were
deep-frozen (liquid nitrogen) and used for the
experiments.
Adhesion assay
Three biological replicates of bEnd5 cells were grown to
build a monolayer as described above using a 24-well-
plate (Greiner bio-one). After treatment with DTX (24 h,
5 ng/mL, ctrl., DMSO 1:1000) bEnd5 cells were washed
2x with PBS and 1000 MDA-MB-231-BR-GFP cells in
MCDB 131 full medium were added to the insert and
put in a humidified incubator for 70 min before being
washed (3x with PBS) to remove the non-adherent cells
and fluorescent signal was counted representing the
remaining adherent GFP-expressing BR231 cells.
Transendothelial electrical resistance (TEER)
MBMECs were isolated as described above and seeded
(100.000 cells/cm2) on fibronectin-coated (5 μg/cm2, 30
min, Sigma-Aldrich) inserts (Greiner Bio-One, Thin-
Cert™, 1 μm pore diameter, 24 well plates). After transfer
to the cellZscope® device (Nano-Analytics, Münster,
Germany), placed in a humidified incubator (37 °C, 5%
CO2), TEER values were obtained from continuous im-
pedance measurements as described previously [23].
After reaching a plateau in TEER levels (establishment
of the endothelial-cell-monolayer) cells were treated with
different concentrations of DTX (5 ng/mL; 500 ng/mL)
for 48 h to 96 h. Statistical analyses were performed
using Prism 6.0 (GraphPad Software, San Diego, CA,
USA), paired t-test.
Permeability assay
bEnd5 cells were cultured on 24-well inserts to build a
monolayer as described above, before being treated with
DTX (5 ng/mL) or DMSO-control (0.25%) for 72 h.
Afterwards, for permeability assay, fluorescent tracers of
different sizes (0.45 kD LY (Sigma-Aldrich), 3 kD TXR
dextran (Thermo Fisher Scientific, Dreieich, Germany),
20 kD TMR dextran (Sigma-Aldrich), 70 kD FITC dex-
tran (Sigma-Aldrich)) were used as described previously
[23] at the following timepoints: 1 h, 2 h, 3 h. Briefly, the
tracer mix was added to the upper chamber and at each
time-point media aliquots from both chambers were
collected. Samples were read in a fluorescence plate
reader (Tecan, Männedorf, Switzerland) at the corre-
sponding tracer excitation/emission. Permeability was
calculated as follows: bottom chamber fluorescence nor-
malized to the apical chamber fluorescence with the ra-
tio for the control condition set to 100% [25]. Statistical
analysis was done using Prism 6.0 (GraphPad software),
unpaired t-test.
RNA isolation and quality control for qPCR
bEnd5 cells were cultured and treated equivalently to
the permeability assay (72 h; DTX (5 ng/mL); DMSO-
control (0.25%)). Total RNAs were extracted using the
RNeasy Mini kit (Qiagen, Hilden, Germany) according
to the manufacturers protocol. RNA purity was moni-
tored using NanoDrop® ND-1000 spectrophotometer
(Thermo Fischer Scientific).
Real-time quantitative PCR (qPCR)
1 μg of total RNA was subjected to reverse transcription
using RevertAid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific). Quantitative PCR (qPCR)
was carried out using Fast SYBR Green Master Mix and
the MyiQ single color real-time PCR detection system
(BioRad, Hercules, CA, USA). Relative fold change (rfc)
was calculated using the ΔΔCt method. Gene expression
was normalized to house-keeping gene G6PDX. Detailed
information about targets and primers is presented in
Additional file 4: Table S2. The figures show data ob-
tained from at least three independent experiments.
Statistical analyes were performed using GraphPad
Prism version 6.0 (GraphPad Software). Quantitative
data was assessed for significance by unpaired student’s
t-test between the control- and the experimental
conditions.
Protein extraction and quantification
After having built a monolayer on 6-well plates as de-
scribed above, bEnd5 cells were treated with DTX (5 ng/
mL) for 24 h or 72 h. After washing twice with ice-cold
PBS, 200 μL/well HES-Buffer (10 mM HEPES, 1 mM
EDTA, 250 mM sucrose, pH 7.4 with protease- and
phosphatase inhibitor cocktail (HALT) 10 μL/1 mL HES)
was added, followed by scraping with a cell lifter and
transferring to a tube (Eppendorf, Wesseling-Berzdorf,
Germany) with consecutive sonication (3 × 3 s, low
power) and centrifugation. Isolated cell lysate super-
natant was either used directly or deep frozen (− 80 °C)
for later use. Protein concentration was determined
using Pierce™ BCA Protein Assay Kit (Thermo Fisher
Scientific) according to manufacturer’s protocol, with
measurement being performed using Tecan plate reader
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at A562 wavelength. For Western blotting 20 μg protein/
sample was used.
Western blotting
Samples were solubilized in urea sample buffer (1X SB;
3X SB = 8.5 M Urea, 7.5% w/v SDS, 0.25M Tris-base
pH 6.8, dissolved in Millipore water to 400 μL, add: 5 μL
0.5% w/v bromphenol blue, 95 μL TCEP; mix: 2:1 (20 μg
Protein/SB)) for 1.5 h (shaking, 30 °C). After loading the
samples on polyacrylamide gels (7–12.5%) according to
the molecular weight of the protein of interest, electro-
phoresis was performed in one of the two ways (1: 20
min 80 V, 1–1.5 h 120 V, RT or 2: 2-3 h 80 V, RT). After-
wards proteins were blotted on a nitrocellulose mem-
brane in one of two ways: (1: 1 h 100 V on ice, RT or 2:
20 h 36 V on ice, 4 °C). After blocking step (1 h, RT, 1x
Roti®-block, Carl Roth GmbH, Karlsruhe, Germany),
membranes were washed (2x PBS-T, 1x PBS, 10 min as
described in detail peviously [25, 26]) and incubated with
the respective primary antibody overnight at 4 °C, shak-
ing (Table 2). After repeated washing and incubation
with horseradish peroxidase-labeled secondary antibody
(1 h, RT, shaking), imaging was performed using the
Odyssey imaging device (LI-COR Biosciences, Lincoln,
NE, USA), using a chemiluminescence system with a
Luminol kit for protein band detection. For repetition of
immunostaining on the same membrane, stripping (15
min, Restore™ PLUS Western blot stripping buffer,
Thermo Scientific, Rockford, IL, USA), washing and
blocking was consecutively performed. For quantification
of protein bands, Image Studio Lite Vers. 5.2 (LI-COR)
was used. Pixel density was measured for each band,
background subtracted, normalized to loading control
for each protein and recalculated to control DMSO set
to 100% for better visualization. For statistical analysis, a
two-tailed unpaired t-test was performed in GraphPad
Prism version 6.0 (GraphPad Software).
bEnd5 cell-pellet generation and staining
After having reached a sub-confluent cell monolayer (T-
75 cell culture flask, Greiner Bio-One) as described
above, bEnd5 cells were treated with DTX (5 ng/mL) for
24 h or 72 h. After washing with PBS, accutase (5 mL,
15 min, Sigma-Aldrich) was added until detachment of
cells was observed. PBS was added and cells were har-
vested for centrifugation (400x g, 5 min). The super-
natant was discarded and PFA was added (4%, 4 mL, 48
h). Afterwards the cell pellets were processed using stan-
dardized protocols for FFPE-tissue, cut into 3 μm thick
slices and placed on a microscope slide (SuperFrost,
Thermo Fisher Scientific), heated to 41 °C for 20 min
and stored at 37 °C overnight in an incubator, followed
by staining as described above using the automated IHC
slide staining system Discovery XT (Roche/Ventana,
Tucson, Arizona, USA) with the antibodies and dilutions
depicted in Table 2. The stained tissue-slides were
Table 2 Antibodies for Western blot (WB), immunohistochemistry (IHC) and immunofluorescence (IF) analyses
Antibody Company Catalog # Dilution (WB/ IHC/ IF)
α-tubulin Sigma-Aldrich T6199 1:1000/ X/ X
β-tubulin Abcam ab6046 X/ X/ 1:200
β-actin Abcam ab8227 1:1000/ X/ X
Claudin-5 (rb) Thermo Fisher Scientific 34–1600 1:500/ 1:200/ 1:200
Claudin-5 (ms) Invitrogen 35–2500 X/ X/ 1:200
Zonula-Occludens-1 Thermo Fisher Scientific 61–7300 1:500/ 1:500/ 1:200
Occludin Thermo Fisher Scientific 71–1500 2 μg/mL/ 1:50/ X
Occludin Invitrogen OC-3F10 X/ X/ 1:200
VE-Cadherin Santa Cruz Sc-6458 1:500/ 1:200/ 1:200
Tie-2 R&D AF762 0.1 μg/mL/ 1:200/ X
pTie-2 R&D AF2720 0.5 μg/mL/ 2.5 μg/mL
ABCC4 Cell signaling 12857S 1:1000/ X/ X
wide-spectrum CK Abcam ab9377 X/ 1:20/ X
anti-mouse IgG Dianova 115–035-146 X/ 1:500/ X
GFAP Dako ZO334 X/ X/ 1:5000
Iba1 Wako 019–19,741 X/ X/ 1:500
Ang2 Thermo Scientific PA5–27297 1:5000/ 1:800/ X
CD31 (rt) Dianova DIA-310 X/ X/ 1:200
DAPI invitrogen D1306 X/ X/ 1:1000
ms mouse, rb rabbit, rt rat
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analyzed for differential staining intensity and gross
morphological changes, using a light microscope (Olym-
pus, Hamburg, Germany) with consecutive acquisition
of representative images.
Chamber-slides staining
Nunc™Lab-Tek™ II Chamber Slide™ System Permanox®
(Thermo Fisher Scientific) was used for culturing of
MBMEC monolayer as described above. After forming a
monolayer, cells were treated with DTX (500 ng/mL) vs.
control (DMSO 1:1000) for 24 h or 72 h. Afterwards, the
slides were washed and stained as described previously
[26] using the following antibodies: VE-Cadherin,
Claudin-5, Occludin, ZO-1, CD31, β-tubulin (Table 2).
Briefly, after washing steps in PBS, cells were fixed using
methanol (100%, − 20 °C, 4 min) or PFA (4%, RT, 10
min), blocked (30 min, PBS containing 0.5% BSA, 0.1%
Triton X-100 and the same buffer for primary and sec-
ondary antibodies) and incubated with the respective
primary antibody for 1 h (RT) and secondary antibody
for 1.5 h (RT), then counterstained using DAPI (1:1000,
5 min, RT). Representative images were taken using
Nikon 80i microscope (Nikon, Düsseldorf, Germany).
RNA preparation and quality control for RNA-sequencing
Cells (MBMEC, HBMEC) were isolated as described
above (pooling of 6–7 mouse brains for each biological
replicate (C57BL/6-WT, 7 weeks, female) for a total of 3
independent experiments for each condition (HBMEC:
DTX-treatment n = 3, DMSO-control n = 3; MBMEC:
DTX-treatment n = 3, DMSO-control n = 3)). After EC-
isolation, cells were washed with PBS and trypsinized to
let them detach. Then, MCDB 131 full medium was
added followed by centrifugation (3 min, 400x g). For
each biological replicate the cell pellet was resuspended
in medium and seeded on to 4 inserts (12-well-inserts),
precoated with fibronectin (5 μg/cm2, 30 min, Sigma-
Aldrich) at 100.000 cells/cm2. The insert comprised
800 μL medium in the upper chamber and 1.5 mL
medium in the lower chamber. DTX-treatment
(HBMEC: 50 ng/mL; MBMEC: 500 ng/mL) was started
after cells were grown to a monolayer (3 days); controls
(DMSO, 1:1000) were treated similarly. After 24 h treat-
ment, the medium was discarded, cells were washed two
times with cold PBS and RNA was isolated inside a ster-
ile hood following the manufacturer protocol using
RNeasy Micro Kit (Qiagen), with the following modifica-
tions: RLT-buffer plus was used with DTT (40 μM) and
samples were homogenized by repeated pipetting and
vortexing (30s). The RNA concentration was determined
using Qubit 3.0 Fluorometer (Thermo Fisher Scientific)
with the manufacturer’s RNA-Kit according to the
standard protocol. RNA-Quality was determined by
Bioanalyzer using the according RNA Kit, to obtain
specific RIN (RNA Integrity Number) values for each
sample.
RNA sequencing and differential gene expression analysis
Libraries were prepared with 500 ng of total RNA using
the TruSeq mRNA Stranded Library Prep Kit (Illumina,
San Diego, CA, USA) according to the manufacturer’s
protocol. Briefly, mRNA pulldown was performed using
an oligodT primer attached to the magnetic beads. To
preserve strand information, the second strand synthesis
was performed with the incorporation of dUTP which in
turn made sure that following the PCR amplification,
only the first stand was amplified. The libraries were
quantified using the Qubit dsDNA HS assay kit (Thermo
Fisher Scientific) and an Agilent 2100 Bioanalyzer (Agi-
lent, Santa Clara, CA, USA). The pooled library was se-
quenced on an Illumina NextSeq500 using the
manufacturer’s instructions. Demultiplexing of the se-
quenced libraries was done using bcl2fastq (v2.18.0.12).
Mapping was performed using star aligner (v 2.5.2b) and
the count matrix was produced using the featureCounts
function from the subread package (v 1.5.2), using
mouse annotation v GRCm38.87 and human annotation
v GRCh38.87. Differential gene expression was per-
formed with DESeq2 (v 1.14.1) using default parameters.
Based on the obtained PCA plots (Additional file 1: Fig-
ure S1) outliers were identified with data being further
analyzed after consecutive exclusion, leading to the final
cleaned data-set (HBMEC: DTX-treatment n = 2,
DMSO-control n = 2; MBMEC: DTX-treatment n = 3,
DMSO-control n = 2), which was further processed for
significance and equally regulated genes between mouse
and human. Briefly, the experimental gene-sets were fil-
tered for significance with consecutive data reduction
for genes with log2fc leading into the same direction for
mouse and human samples, resulting in the final gene-
set.
Murine brain metastatic model
Eight to twelve weeks old female Balb/c nude mice (Har-
lan Olac Ltd., Shaws Farm, Blackthorn, Bicaster, UK)
were treated according to different treatment-schedules
prior to TC injection. To establish BM, 500000 MDA-
MB-231 BR TCs in 0.1 ml PBS were injected into the left
ventricle under isoflurane/O2 anesthesia. DTX was
injected intravenously according to the treatment sched-
ule. DTX effect studies (samples for electron microscopy
(EM), IgG staining) were performed similarly, however
limiting the treatment-schedule to the “multi tax” (5
times) and “no tax” group without TC injection. DTX
(Taxotere, 20 mg/mL, Sanofi-Aventis, Frankfurt,
Germany) was reconstituted as indicated in the manu-
facturer’s protocol, followed by additional dilution (1:10)
in NaCl 0.9% (final concentration: 2 mg/mL). Final
Bernatz et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:434 Page 6 of 21
solution was i.v. injected, 10 mg/kg bodyweight equaling
approximately 100 μL/mouse (mean body weight/
mouse = approximately 20 g). Control mice were treated
equally, receiving 100 μL/mouse in 0.9% saline per injec-
tion. Four weeks after TC injection, mice were eutha-
nized under CO2 asphyxiation and brains were
harvested.
Immunohistochemistry (IHC) and immunofluorescence (IF)
Brains were formalin-fixed (in 4% PFA for 48 h) and cut
into 5–6 consecutive coronal slices and paraffin embed-
ded. Respective tissue blocks were cut into 3 μm thick
slices and placed on a microscope slide (SuperFrost,
Thermo Fisher Scientific), heated to 41 °C for 20 min
and stored at 37 °C overnight in an incubator.
Hematoxylin and eosin staining was performed accord-
ing to a standard protocol. For IHC staining standard-
ized protocols for using the automated IHC slide
staining system Discovery XT (Roche/Ventana) were
used including the following antibodies (Table 2): anti-
IgG (115–035-146; 1:500, Dianova, Hamburg, Germany),
anti-wide spectrum Cytokeratin (CK) (ab9377, 1:20,
Abcam). Afterwards slides were counterstained with
hematoxylin and mounted. IF-staining was manually ob-
tained by following the previously described protocol
[27] for the respective primary antibodies: GFAP
(ZO334, 1:5000, Dakocytomation, Glostrup, Denmark)
and Iba1 (019–19,741, 1:500, Wako, Osaka, Japan).
Stainings were evaluated for tumor foci count (HE, IHC
for CK) following two different approaches to minimize
subjective interpretation bias. First, HE-stained slides
were evaluated for unequivocally distinguishable tumor
foci using a light microscope. Secondly, immunohisto-
chemically wide-spectrum CK stained slides were ana-
lyzed using a light microscope with Stereo Investigator
(Version 4.34 software, MicroBrightField Inc., Williston,
VT, USA), counting of TC metastasis, marked by CK-
staining with subsequent normalization of the number
of foci count related to the counted surface area. IF-
stained slides were visually analyzed for gross morpho-
logical and intensity changes within tumor bearing areas.
Representative images of tumor-bearing areas were
taken using Nikon 80i microscope (Nikon, Düsseldorf,
Germany).
Electron microscopy
For electron microscopy, brains were fixed overnight
using 2.5% glutaraldehyde buffered in cacodylate. The
embedding procedure comprised fixation in 1% osmium
tetroxide, dehydration in a graded ethanol series inter-
mingled by an incubation step with uranyl acetate (be-
tween the 50 and 90% ethanol step) and finally rinsing
in propylene oxide. The specimens were then embedded
in epoxy resins that polymerized for 16 h at 60 °C. After
embedding, first semi-thin sections (0.5 μm) were cut
using an ultramicrotome (Leica Ultracut UCT, Deerfield,
IL, USA) with a diamond knife. Sections were stained
with Toluidine blue, placed on glass slides and examined
by light microscopy to select appropriate areas for ultra-
thin preparation. Ultrathin sections (50-70 nm) were cut
again using an ultramicrotome. Sections were mounted
on copper grids and contrasted with uranyl acetate for
2-3 h at 42 °C and lead citrate for 20 min at room
temperature. These samples were imaged and digital pic-
tures were taken with a FEI Tecnai G2 Spirit Biotwin
TEM (Hillsboro, OR) at an operating voltage of 120 kV.
Representative images being taken with an Eagle 4 K
CCD bottom-mount camera.
In vivo injections and magnetic resonance imaging (MRI)
DTX or 0.9% saline was injected as a bolus over 30s into
the tail vein of 3 female and 7 male 4–6 months old
NOD/SCID mice with an average bodyweight of 25.6 g.
In the first experiment, 3 mice received 10 mg/kg DTX
intravenously (i.v.) [28] (2 mg/mL dissolved in 0.9% sa-
line) once a week for 4 weeks (4 injections in total),
while 3 control mice received 0.1 mL 0.9% saline i.v.
once a week for 4 weeks. In the second experiment, 2
mice received 10mg/kg DTX intravenously (i.v.) (2 mg/
mL dissolved in 0.9% saline) every second day for 6 days
(days 0, 2, 4 and 6; 4 injections in total), while 2 control
mice received 0.1 mL 0.9% saline i.v. every second day
for 6 days. In both experiments, dynamic contrast en-
hanced MRI (DCE-MRI) was performed approximately
60 min after the last injection. As a positive control for
permeabilization of the BBB, 3 female mice were given
200 mg K16ApoE dissolved in 100 mL 0.9% saline in the
tail vein over 60s, and DCE-MRI was obtained 15min
after injection. K16ApoE is a peptide consisting of apoli-
poprotein E and 16 lysine residues and its ability to
permeabilize the BBB has been described previously
[29]. MRI was carried out using a 7 Tesla small-animal
horizontal MR scanner (Bruker BioSpin GmbH, Ettlin-
gen, Germany), using a 72mm quadrature transmit coil
and a 4-channel mouse brain array receive coil. The ani-
mals were placed in prone position and the body
temperature was maintained at 37 °C. T1 and T2
weighted spin echo scans were acquired prior to DCE-
MRI to provide anatomical references. The T2 weighted
scans were acquired in coronal positioning (TR/TE:
4000/48 ms, field of view (FOV): 2.00 cm, matrix size:
256 × 256, slice thickness: 1.00 mm, 7 slices and number
of averages (NEX): 4, total scan time 6min 13 s). The T1
weighted scans were acquired with the same geometry
as the T2 weighted scans (TR/TE 1000/9 ms, and NEX:
4, total scan time 3min 20s). The DCE-MRI sequence
consisted of 900 repetitions of the FLASH protocol with
the same geometry as the T1 and T2 weighted sequences
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(TR/TE: 15 ms/2.1 ms, NEX: 1, FA: 17, temporal reso-
lution: 1 s and total scan time 16 min 12 s). 0.5 mmol/kg
Omniscan (GE Healthcare, Little Chalfont, UK) was
injected as a bolus during 20s through the tail vein using
an injection pump (Harvard Apparatus, Holliston, MA,
USA) 15 s after starting the DCE-MRI sequence.
The DCE-MRI data was analyzed using the Extended
Tofts model, implemented in nordicICE v2.3.14 (Nordic
NeuroLab, Bergen, Norway), using local arterial input
functions (AIFs), obtained from adjacent arteries. Maps
of Area Under the Curve (AUC) were generated in two
regions of interest (ROIs; areas 14mm2 (Fig. 3e) or
65mm2 in the mouse brain sections. Mean and standard
deviation values were calculated for each ROI, and po-
tentially statistically significant differences in AUC
values between DTX- or K16ApoE-receiving animals
and corresponding 0.9% saline receiving animals were
determined using a two-sided Student’s T-test, with a
significance level of 0.05.
Statistical analysis
Statistical analyses were conducted using Prism 6.0
(GraphPad software) or JMP 14 (SAS, Cary, U.S.A.). For
statistical analysis, a p-value < 0.05 was considered as
significant and depicted in the graphs as followed: * p <
0.05; ** p < 0.01; *** p < 0.001. Information about experi-
mental repeats and employed tests is indicated in the
corresponding method section or figure legend.
Results
Taxane treated mBC patients show higher incidence of
CNS metastases
The conflicting data about whether or not taxane treat-
ment leads to an increased rate of BM prompted us to in-
vestigate our own patient cohort (n = 80). The patient
characteristics and tumor biological parameters are sum-
marized in Table 1. Patients were reviewed retrospectively
according to a case-control approach: BM (BM, exp., n =
40) vs. no BM, but bone metastases (BoM, ctrl., n = 40), to
test for the possibility that taxane-treatment (DTX or pac-
litaxel) may be associated with an increased development
of BM. In our monocentric, BC patient cohort, patients
who progressed to brain metastatic disease were found to
having significantly more often received taxane-treatment
in the course of their disease than the nBM- subcohort
(Fig. 1a). Taxane-treated vs. non-taxane-treated (n = 68 vs.
n = 12) patients showed comparable duration of follow-up
since primary diagnosis (Fig. 1b). Also, there was no differ-
ence regarding the start of taxane treatment or follow-up
related to the taxane treatment (Additional file 2: Figure
S2A), but taxane-treated patients were significantly youn-
ger at their BC-diagnosis (Fig. 1c). BM and BoM patients
were relatively similar concerning the administered tax-
anes, DTX/paclitaxel (Fig. 1d). BM and BoM patients did
not differ in survival (Additional file 2: Figure S2B). Me-
dian interval between BC diagnosis to BM development
was 4.879 years (Additional file 2: Figure S2C). However,
the cohorts significantly differed concerning the BC intrin-
sic subtypes (Fig. 1e). BM patients were, in univariate ana-
lysis, significantly more often ER negative, PR negative
and triple negative, but did not differ with regard to
HER2/neu (Fig. 1f). Notably, ER being negative and taxane
treatment remain the only significant risk factors for BM
formation in the consecutive multivariate analysis (p =
0.003; p = 0.018) (Fig. 1f).
DTX treatment increases CNS metastasis formation in a
murine intracardiac TC injection model
To further study DTX effects on BM formation, we used
a murine model in which mice were pretreated with
DTX (10mg/kg body weight) prior to intracardiac (left
ventricle) injection of MDA-MB-231 BC cells, according
to three different treatment regimens: multi DTX (5
times), short DTX (2 times), no DTX (Fig. 2a); followed
by neuropathological assessment (Fig. 2b-e). Microscopic
assessment of the murine brains confirmed a mainly
perivascular infiltration pattern of the TCs, whereas a
spread to the cerebrospinal fluid, or superficial metasta-
ses was rarely observed (Fig. 2b). Immunofluorescence
(IF) analysis of astrocytes (GFAP) and microglia (Iba1)
showed increased activation of both cell types surround-
ing tumor foci, without associated DTX-specific changes,
corroborating a well working BM-model [30] and nicely
mimicking BM distribution usually observed in patients
[31] (Fig. 2b-d). Differences in BM foci were observed
between the groups, with a significantly higher amount
of BM in the “multi DTX” group as compared to “no
DTX” (p = 0.012 (for HE); p = 0.026 (for CK)), and a
strong trend as compared to “short DTX” (Fig. 2e, f).
DTX treatment does not impair BBB permeability in-vivo
As DTX treatment enhances BM-formation and brain
blood vessel homeostasis and integrity is mainly provided
by the BBB [32], we next investigated BBB properties and
potential DTX-induced BBB alteration in mice in-vivo by
means of IHC, EM and DCE-MRI. First, light microscopic
immunohistochemical IgG-staining of DTX-treated
mouse brain showed no change of permeability as com-
pared to controls (Fig. 3a). Along this line, ultrastructural
analyses of DTX-treated mice revealed no relevant
changes of the NVU such as unequivocal disruption of
tight-junctions or relevant morphological alterations of
endothelial cells (ECs) or respective organelles (Fig. 3b).
In our DCE-MRI analysis, we first compared animals
receiving either 4 i.v. injections of DTX over 4 weeks,
with control animals receiving 4 i.v. injections of PBS
over 4 weeks. No statistical differences in AUC could be
found (p = 0.672; Fig. 3c). We then treated animals with 4
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Fig. 1 Incidence of CNS-involvement is increased in taxane-treated mBC patients. a Contingency analysis with likelihood-ratio and Pearson test of
taxane-treatment (yes/no) for BM- vs. nBM-cohort. b, c Non-parametric multiple comparisons for each pair using Wilcoxon-method: b Follow up
“primary diagnosis” (N (notaxane) = 12, N (taxane) = 68); c Patient age primary diagnosis (N (notaxane) = 12, N (taxane) = 68). d, e Contingency
analysis with likelihood-ratio and Pearson test of (d) administered taxane (N (nBM) = 30, N (BM) = 38, N varies from 40 as the non-taxane-treated
subcohort was excluded for the analysis) and (e) intrinsic subtypes (N (nBM) = 40, N (BM) = 40) for BM- vs. nBM-cohort. f For univariate analysis,
effect likelihood ratio and odds ratio test was used; for multivariate analysis nominal logistic fit for the endpoint BM-development using effect
likelihood ratio test was applied. Statistical analysis was performed using JMP 14.0.0 software (SAS)
Fig. 2 DTX-pretreatment in balb/c nude mice increases CNS metastatic load after intracardiac TCs injection. a Experimental setting of the animal
model. b Representative HE and immunohistochemical (wide-spectrum cytokeratin) stainings of established tumor foci (original magnification 10x
or 20x). c, d Representative IF-stainings of microenvironmental changes surrounding established tumor foci of different sizes and treatment
groups: staining for (c) astrocytes (GFAP), d microglia (Iba1) (images taken with the Eclipse 80i fluorescent microscope; scale bar, 50 μm). e, f One
way ANOVA with Kruskal-Wallis test for CNS tumor foci count performed either in (e) HE- or (f) wide-spectrum cytokeratin IHC-staining. Statistical
analysis was done using GraphPad Prism software
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i.v. injections over 6 days, either with DTX or PBS. Also
here, no differences in AUC could be found (p = 0.926,
Fig. 3d), whereas positive control animals (one injection of
K16ApoE) showed a prominent permeabilization of the
BBB (p = 0.018, Fig. 3e). Transient local permeability
changes may be rather difficult to detect in-vivo, so we
next performed in-vitro experiments.
DTX-treated ECs do not lead to more adherence of TCs
Regarding the metastatic cascade, adhesion and subse-
quent transmigration take place during BM-formation
[33]. Therefore, we checked if DTX-pretreated ECs may
lead to an increased adhesion of MDA-MB-231 TCs
(GFP-labeled) plated above the ECs, however no signifi-
cantly enhanced TC adhesion could be observed in the
ECs that have been treated with DTX (Fig. 4).
In-vitro BBB-permeability is increased upon DTX-
treatment with concentration-dependent kinetics
An in-vitro BBB-model was applied to address a potential
transient DTX impact on the BBB. BBB-permeability was
assessed with TEER-measurements, a sensitive method to
study EC-monolayer integrity and permeability [34], with
loss of resistance paralleling increased permeability (Fig. 5).
TEER-measurements showed a continuous increase of re-
sistance until reaching the plateau phase, where the treat-
ment was started, which resulted in a steady decrease of
resistance in DTX-treated bEnd5-cells within our observa-
tion frame (Fig. 5a). Also, permeability to different sized
fluorescent-labeled agents (kDa: 70; 20; 3; 0.45) was in-
creased in DTX-treated bEnd5 cells. Two tracer sizes (kDa:
70; 0.45) showed significant increase in permeability for
one and a strong trend for the other time points. The 3
kDa-tracer was significantly altered for all time points and
the 20 kDa tracer was not significant but showed a strong
trend for all time points (Fig. 5b). Those findings led us to
verify the results using primary MBMECs and we found
DTX-treatment leading to concentration-dependent per-
meability changes; showing a minimal, non-significant
trend at the dose of 5 ng/mL-DTX (Fig. 5c, d), and a stron-
ger TEER-decrease at 500 ng/mL-DTX, with leakage being
significant around 36–48 h (36 h p = 0.021; 48 h p = 0.02)
after the treatment, and being again absent with a trend to
even tightening the BBB after 72 h (Fig. 5e, f).
(See figure on previous page.)
Fig. 3 Permeability analyses of DTX-treated mice in-vivo do not show signs of increased leakage. a Exemplary IHC-stainings of murine IgG using brain
sections of DTX-treated vs. control mice (original magnification 20x). b Representative images of ultrastructural NVU-imaging: ECs (indicated by *); TJs
(indicated by➔); perivascular axons (indicated by <=; mitochondria (indicated by >); basement membrane (indicated by .--.); erythrocyte (indicated by e).
Images taken using Tecnai Spirit BioTWIN FEI EM at 120 kV, with 4 K CCD camera. c-e DCE-MR imaging heatmaps of treated vs. untreated mice for in-vivo
permeability analysis. Statistical analysis was conducted using student’s t-test, subset analysis for three different groups as depicted in the methods section
Fig. 4 TCs do not show increased adhesion on EC monolayer upon DTX treatment. Representative images of the adhesion assay showing GFP-
labeled (*) MDA-MB-231-BR-GFP-TCs on top of ECs monolayer. Phase-contrast microscope with IF-imaging, original magnification 4x, 40x.
Unpaired t-test of treated (N = 3) vs. untreated (N = 3) bEnd5 cells monolayer, with TCs plated on top. Statistical analysis was done using
GraphPad Prism software
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Unaltered tight junction protein expression and a delayed
increase of VE-cadherin protein expression, upon DTX
treatment
We next analyzed possible molecular components of
DTX-induced increase in permeability in-vitro, by qPCR,
WB and immunostainings of ECs (Fig. 6). Selected can-
didates were first screened by qPCR. A trend towards in-
creased expression upon DTX treatment was observed
for the junctional molecules VE-Cadherin and Claudin-
5, as well as for a variety of pumps, known to play im-
portant roles in ECs [24] (Fig. 6a). The strongest trend
of increased expression was shown for Angiopoetin-2 al-
though not reaching the threshold level of significance
(p = 0.133; Fig. 6a). Next, appropriate candidates were
analyzed by WB. With regard to 24 h DTX-treatment,
no significant change of protein levels could be observed
for any proteins including those involved in tight-
junctions (ZO-1, Occludin) (Fig. 6b, c). The proteins
known to be able to alter BBB-permeability, related to
the trend of increased Ang2-level, with the respective
axis of Tie2 and pTie2, were not altered [35] (Fig. 6b, c).
Also the MDR-pump ABCC4, as important BBB efflux
transporter [24, 36], was not affected (Fig. 6b, c). 72 h-
treatment paralleled above effects, with the exception of
Claudin-5 being significantly upregulated in the DTX
group (Fig. 6b, c). Further, microscopic analysis of IHC-
stained ECs cell-pellets did not show distinct DTX-
treatment related protein alterations, supporting the WB
data (Fig. 6b).
Altered endothelial ß-tubulin distribution and nuclear
morphology but not BBB associated molecules upon DTX
treatment
As junctional protein-levels were not changed, we inves-
tigated if their intra−/ intercellular distribution,
organization or morphology may be altered using IF-
stainings of primary MBMEC monolayers with EC-
origin being assured by comprehensive CD31 marker ex-
pression (Fig. 7a). DTX-treatment resulted in disturbed,
coarse tubulin-morphology (Fig. 7a). A uniform mono-
layer was established in both groups associated with a
global expression of junctional proteins (Fig. 7). IF
microscopic analysis revealed no relevant changes of
morphology, distribution or organization of the analyzed
proteins, although DTX treatment impaired elongation
of EC nuclei, induced occasional karyorrhexis and led to
reduced EC density (Fig. 7b). Treatment was started
when the monolayer mainly presented in an unorganized
growth pattern and interestingly, after 72 h, the control
group displayed already large areas of typical spindle
shaped morphology of mature BBB forming ECs,
whereas the DTX-group comprised mainly an disorga-
nized coarse pattern lacking smooth cell-cell borders
(Fig. 7c).
Human and murine DTX-treated ECs show a common
candidate gene set potentially involved in EC alteration
For deeper analysis of the underlying mechanism on the
molecular level, RNA-sequencing was performed using
primary cultured brain ECs from mouse (MBMEC) and
human (HBMEC) after 24 h of DTX treatment in-vitro.
First, mRNA-sequencing-data were processed for differ-
ential expression (DeSeq2), then overlapping signifi-
cantly and equivalently regulated genes from mouse and
human were analyzed (Table 3). Similar regulation was
found for different members of the tubulin family (β 2B,
β 2A, α 4A, α 1A) which are involved in forming the
microtubule-structures, being upregulated and only one
other protein-coding gene, namely TSPAN2, which
codes for Tetraspanin-2, which was downregulated
(log2foldchange: ms = − 0.475; hu = − 1.513) (Table 3).
Discussion
The brain displays the most dramatic site for cancer me-
tastasis [37] with limited available therapeutic ap-
proaches [37, 38]. Therefore it is of importance to
identify risk factors, leading to BM formation [37].
Though controversial data exist concerning a possible
increase of CNS-involvement in BC-patients treated with
a chemotherapeutic agent of the taxane family, the ques-
tion whether or not taxane treatment may alter BBB-
properties, facilitating TC transmigration into the brain
and thus establishing of BM, was never experimentally
addressed [20–22]. Our results demonstrate a positive
association between taxane treatment and BM formation
with a significantly increased BM rate in both BC pa-
tients and a BC mouse model, suggesting a direct effect
of taxanes on BBB function.
Previous studies proposed the CNS as sanctuary site
for TCs [13, 21], showing that adjuvant chemotherapy
may lead to a higher frequency of BM [21, 39]. Also a
transient chemotherapy induced BBB-alteration, which
might facilitate TC transmigration across the BBB into
the brain parenchyma is discussed [4].
(See figure on previous page.)
Fig. 5 DTX-treatment increases BBB-permeability in-vitro in a concentration-dependent manner. a Representative image of bEnd5 cells
monolayer in TEER-measurement. b Permeability assay of treated (N = 3) vs. untreated (N = 3) bEnd5 cell monolayer, using different sized tracers
(kDa 0.45; 3; 20; 70). Statistical analysis: unpaired t-test using GraphPad Prism Software. c Illustration of TEER-curve progression using primary
MBMECs with DTX-treatment ((c) 5 ng/mL; e 500 ng/mL) vs. control and subsequent statistical analysis with GraphPad Prism software, using
paired t-test (d, f). start of treatment, #
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Controversial results have been reported about the
question if chemotherapeutic agents from the taxane
family lead to an increase of CNS-relapse in BC-patients:
(i) high rate of CNS-relapse (17.9% of initial treatment-
responders) was seen by Freilich et al. [21], who investi-
gated 152 patients with different doses and schemes of
paclitaxel therapy being applied. However, no control
group was analyzed in this study; (ii) high frequency of
CNS-involvement (30.4%) was shown by Crivellari et al.
[22], investigating 92 patients being treated with Epirubi-
cine and DTX, yet also this study missed an adequate
control group and (iii) no increased BM-frequency (no
taxane-treatment: 4%; taxane-treatment: 3.7%) was
shown in the study of Pestalozzi et al. [20], investigating
2887 npBC patients prospectively, however results were
limited by study design as for CNS-relapse analysis only
the 403 patients who died within the follow up of 5 years
were investigated, resulting in 110 patients with BM; pa-
tients suffering from non-symptomatic BM were not in-
cluded. As literature findings describe CNS involvement
in breast cancer patients as being highly heterogenous,
ranging from 3.9–20% (or even up to 30.4%, Crivellari
et. al) [22, 40], a valid power analysis of our patient co-
hort was not achievable. In our small, monocentric pa-
tient cohort, taxane treatment was significantly
positively associated with BM formation as compared to
a bone metastatic control group (Fig. 1a). Patients re-
ceiving taxanes were significantly younger (Fig. 1c) and
BM patients were significantly more often TN, PR- or
ER negative (Fig. 1f), all factors known to be associated
with increased BM development [41, 42]. Also, the co-
horts differed with regard to the BC intrinsic subtypes
(Fig. 1e), with the BM-cohort incorporating significantly
more often basal-like- and Erb-B2 overexpressing sub-
types which are known to show a high rate of BM [43,
44]. We did not include the Ki-67-proliferative index,
because no generally accepted, comprehensive recom-
mendation for standardization is available yet, which let
us to combine the intrinsic subtypes Luminal A and -B
into one subtype [15, 44]. We performed a multivariate
analysis with taxane treatment still being significantly as-
sociated with an increased risk of BM formation while
the other factors, except ER being negative, were no lon-
ger significant (Fig. 1f). Nevertheless, our cohort suffers
from major limitations such as its retrospective design,
incomplete data for some patients, a rather small sample
size, significant differences in tumor biology and intrin-
sic subtypes, non-significant differences in survival, as
well as the administration of a broad spectrum of medi-
cation. Taken together, the epidemiologic finding of
DTX-effect (Fig. 1) is critical and needs to be discussed
but should not be overstated. The question if taxane
treatment is a relevant factor for increased BM develop-
ment and may confer single TCs an increased probabil-
ity to cross the BBB cannot be answered by analyzing
patient data only. Therefore, we used a previously de-
scribed murine BM model [45]. To study DTX effects
on blood-vessels, without being biased of sanctuary TC
growth [13, 22], mice were pretreated with DTX prior to
TC injection, therefore interactions between DTX and
TCs can be ruled out in our setting (Fig. 2a). We used
MDA-MB-231-BR-GFP cells as they have a tropism to
metastasize to the brain [45]. Our results demonstrated
an increased amount of BM foci paralleling increasing
DTX levels with a mainly perivascular infiltration pat-
tern (Fig. 2e, f), nicely mimicking brain metastatic coop-
tive growth pattern [33, 37] (Fig. 2b).
Cells can pass the BBB either via paracellular or
transcellular routes [33]. The former requires that the
cells pass through intercellular junctions, which is fa-
cilitated when permeability is increased [33]. How-
ever, we could not observe relevant alterations of the
BBB permeability upon DTX treatment in-vivo (Fig. 3).
Prior to transmigration, TCs need to attach to the
ECs in a selective manner or via a mechanical arrest,
similar to a thrombus plugging the blood vessel in is-
chaemic stroke [7, 46, 47]. Therefore, we hypothe-
sized that DTX may lead to increased adhesion in-
vitro, but also here, no differences were observed
(Fig. 4). Of note, not a single human tumor cell
showed plane adhesion nor migration upon or
through the murine EC monolayer pointing to interspe-
cies differences [48]. Consequently, our murine metastatic
model might not be able to reveal this specific adherence
step of the metastatic cascade which may hereby be ruled-
out as being crucial for the observed increased BM-
frequency. In our model, intravascular tumor cell arrest
most probably occurs mechanically by plugging the vessel
and subsequent transmigration [7]. It is known that TC
transmigration damages ECs, leaving apoptotic cells and a
debilitated barrier behind, a suitable entry point for close-
by TCs [49, 50]. Furthermore, DTX impacts endothelial
proliferation-status, reduces wound-healing capacities [51,
52] and sensitizes ECs to hypoxic damage [53], all factors
potentially facilitating TC transmigration and thereby in-
creasing BM foci.
(See figure on previous page.)
Fig. 6 qPCR, WB and ICC target analyses of DTX-treated bEnd5-cells. a Differential mRNA expression analysis by quantitative polymerase chain
reaction (qPCR) of three independent experiments, treated (N = 3) vs. ctrl (N = 3) ECs, using unpaired student’s t-test, GraphPad Prism software. b
Analysis of WB data (N = 3 treated vs. N = 3 ctrl) using unpaired student’s t-test. Exemplary images of respective bEnd5 cell-pellet IHC-stainings
(original magnification 40x). c Respective immunoblots used for statistical analyes of WB data, each pair of −/+ represents a biological replicate
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Fig. 7 IF analyses of junctional BBB signature-proteins in MBMEC-monolayer. Representative IF-stainings of signature BBB-proteins. a 24 h
treatment; b, c 24 h and 72 h treatment as depicted, (a, b) scale bar, 20 μm; karyorrhexis, <; c scale bar, 50 μm
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Considering the possibility of insufficient sensitivity of
hitherto in-vivo BBB-permeability analysis, we used an in-
vitro BBB model with continuous TEER-measurement,
known to be a sensitive and reliable method to analyze EC-
monolayer tightness and integrity [24, 34] (Fig. 5). As TEER
only measures permeability to ions [25, 54], we also
checked permeability with regard to the tracers of different
sizes, which was increased either significantly or with a
strong trend after DTX treatment. First, to keep the animal
number as low as possible, we used immortalized murine
ECs (bEnd5), being a suitable cell-line for BBB-analyses
[24]. Further, we corroborated those findings using primary
MBMECs for TEER-measurements, as they display best in-
vitro/in-vivo comparability [24, 36], revealing BBB-
impairment positively correlating with the used DTX con-
centration in time and extent, to finally being hypercom-
pensated, leading to an increased tightening of the BBB.
We further analyzed a subset of previously described BBB
signature markers [24, 33, 36, 55] to elaborate possible mo-
lecular components associated with DTX-associated per-
meability increase in-vitro, including the Ang/Tie2-axis
which is known to have an impact on vessel integrity, with
Ang2 contributing to vessel destabilization [35] (Fig. 6).
Nevertheless, the weak trend of increased Ang2 mRNA-
levels could not be corroborated at protein level. There
were no changes which would indicate an unequivocal BBB
leakage, however the significant increase of Claudin-5 after
72 h treatment could be interpreted as being part of a com-
pensatory tightening effect (Fig. 6b, c). We also investigated
a potential impairment of junctional protein distribution,
arrangement and morphology (Fig. 7). It has been shown
for epithelial cells that besides actin [56], microtubules are
essential for TJ homeostasis and restoration [57]. Prior
studies reported an attenuated disassembly of epithelial and
endothelial junctional proteins upon taxane-induced micro-
tubule stabilization [58–60]. Further, disruption of microtu-
bules significantly reduced barrier functions in TEER-
assays, highlighting the importance of interaction between
microtubules in junctional preservation [57]. Our
immunostaining-based morphologic analysis proved
tubulin-affection, whereas junctional proteins did not show
relevant changes. Interestingly, DTX treatment inhibited in-
duction of the organized ECs growth pattern being in line
with previous studies showing that DTX treatment impairs
EC migration [52] and attenuates junctional disassembly
[58]. This may also explain the attenuated barrier compen-
sational capacities, especially after EC-damage.
Based on the stated functional findings but scant identi-
fication of molecular targets, we went for mRNA-
sequencing. The unexpected finding that most of the sig-
nificantly regulated genes did not match between mouse
and human ECs, let us to interpret the matching genes as
being the most important, obtaining 5 significantly regu-
lated genes (Table 3). Various members of tubulin families
were upregulated upon DTX treatment, which served well
as proof of principle of achieved DTX effect [61, 62]. The
only otherwise similarly downregulated gene was Tspan2
coding for the protein Tetraspanin-2. Tetraspanin-2 has
indeed reported as being involved in cancer metastasis
and tumor-related angiogenesis [63, 64]. In tumor-
conditioned ECs, epigenetic silencing of Tspan2 was iden-
tified as a driver of angiogenesis corroborated by the direct
angiostatic effect caused by DNA methyltransferase and
histone deacetylase inhibitors-treatment [64]. Additionally,
knockdown of Tspan2 increases ROS production [63],
similarly to DTX [65]. Increased ROS production might
therefore constitute a potential mechanistic link between
Tspan2 and DTX treatment, since it affects the BBB per-
meability among others through TJ protein modulation
[66–68]. Occludin, a crucial tight junction molecule of the
BBB which has been implicated in BBB dysfunction in
hypoxia and ischemic stroke, also belongs to the tetraspa-
nin family [32, 36]. The role of tetraspanin-2, obtained
from our sequencing analysis could potentially be a novel
candidate regulating the BBB function [32, 36] . These as-
pects are in line with our stated hypothesis: tumor cell
clots leading to thrombotic occlusion of blood vessels with
consecutive hypoxia of endothelial cells, that are sensitized
to BBB-damage through DTX treatment thus showing an
increased BBB-impairment, may facilitate tumor cell
transmigration to the CNS. Additionally, DTX-induced at-
tenuated TJ dynamics prolong junctional-recovery [57–
60], leading to a longer time frame of barrier dysfunction
may also facilitate tumor cell transmigration. Finally, the
cascade is potentiated by the pro-angiogenic state of the
ECs. The stated, mechanistic hypothesis was not further
analyzed, therefore needing further investigation.
Conclusion
In conclusion, DTX treatment seems to increase BM
rate in human and mice, hypothesizing a direct effect of
taxanes on BBB properties. This effect seems to be
Table 3 RNA sequencing data showing significant changes in
expression mouse (MBMEC) and human (HBMEC) endothelial
cells
mouse human
log2fc p-value log2fc p-value
Tubb2b 1.315 < 0.001 1.725 < 0.001
Tubb2a 1.212 < 0.001 1.523 < 0.001
Tuba4a 1.472 < 0.001 1.231 < 0.001
Tuba1a 1.231 < 0.001 1.364 < 0.001
Tspan2 −0.475 0.028 −1.513 0.007
Differential expression analysis of mRNA levels of mouse (DTX, n = 3; ctrl, n = 2;
DTX, 500 ng/mL) and human (DTX, n = 2; ctrl, n = 2; DTX, 50 ng/mL) primary
cultured ECs after 24 h of DTX-treatment. Analysis was done using DESeq2
package, based on PCA plot. Outliers were excluded resulting in the above
stated n
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rather transient (TEER), followed by a hypercompensa-
tory (TEER, WB data Claudin-5) state, however with no
morphologically detectable long-term changes (EM, IgG-
IHC). We could not identify a definite mechanism how
DTX treatment impairs BBB properties, however par-
ticularly molecules of the tubulin-family and
tetraspanin-2 seem to be involved. A tight neuroradiolo-
gic follow-up for mBC-patients receiving taxane is pro-
posed and further investigation is needed.
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